Loading...
Follow-up after treatment for molar pregnancy involves monitoring serum human chorionic gonadotropin (hCG) to identify recurrent disease (gestational trophoblastic neoplasia). To determine the optimal duration of posttreatment surveillance, investigators conducted a meta-analysis of 19 studies in which women underwent sequential hCG measurements for ≥6 months after treatment.
After treatment and one normal hCG, risk for recurrent disease was 0.35% (64/18,357) for complete mole and 0.03% (5/14,864) for partial mole. For complete mole, 90% of recurrences occurred among women whose first normal hCG occurred ≥8 weeks following treatment and 60% of recurrences occurred >6 months after the first normal hCG. For partial mole, 60% of recurrences occ…